Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$17.33 USD
-0.05 (-0.29%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $17.35 +0.02 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVDL 17.33 -0.05(-0.29%)
Will AVDL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVDL
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
Other News for AVDL
Jazz Pharmaceuticals: Cheap But Complicated
Avadel Pharmaceuticals call buyer realizes 17% same-day gains
Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference